NO20020087L - Hybride polypeptider med forbedrede farmakokinetiske egenskaper - Google Patents

Hybride polypeptider med forbedrede farmakokinetiske egenskaper

Info

Publication number
NO20020087L
NO20020087L NO20020087A NO20020087A NO20020087L NO 20020087 L NO20020087 L NO 20020087L NO 20020087 A NO20020087 A NO 20020087A NO 20020087 A NO20020087 A NO 20020087A NO 20020087 L NO20020087 L NO 20020087L
Authority
NO
Norway
Prior art keywords
pharmacokinetic properties
hybrid polypeptides
enhanced pharmacokinetic
enhanced
polypeptides
Prior art date
Application number
NO20020087A
Other languages
English (en)
Norwegian (no)
Other versions
NO20020087D0 (no
Inventor
Shawn Barney
Kelly I Guthrie
Gene Merutka
Mohmed K Anwer
Dennis M Lambert
Original Assignee
Trimeris Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trimeris Inc filed Critical Trimeris Inc
Publication of NO20020087D0 publication Critical patent/NO20020087D0/no
Publication of NO20020087L publication Critical patent/NO20020087L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1021—Tetrapeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20020087A 1999-07-09 2002-01-08 Hybride polypeptider med forbedrede farmakokinetiske egenskaper NO20020087L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/350,641 US6656906B1 (en) 1998-05-20 1999-07-09 Hybrid polypeptides with enhanced pharmacokinetic properties
PCT/US2000/018772 WO2001003723A1 (en) 1999-07-09 2000-07-10 Hybrid polypeptides with enhanced pharmacokinetic properties

Publications (2)

Publication Number Publication Date
NO20020087D0 NO20020087D0 (no) 2002-01-08
NO20020087L true NO20020087L (no) 2002-03-01

Family

ID=23377584

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20020087A NO20020087L (no) 1999-07-09 2002-01-08 Hybride polypeptider med forbedrede farmakokinetiske egenskaper

Country Status (22)

Country Link
US (2) US6656906B1 (ru)
EP (1) EP1206272A4 (ru)
JP (1) JP2003504344A (ru)
KR (1) KR100755418B1 (ru)
CN (1) CN1254271C (ru)
AR (1) AR024699A1 (ru)
AU (1) AU6082200A (ru)
BR (1) BR0012287A (ru)
CA (1) CA2377677A1 (ru)
CZ (1) CZ200288A3 (ru)
HK (1) HK1045259A1 (ru)
HR (1) HRP20020022A2 (ru)
IL (1) IL147331A0 (ru)
MX (1) MXPA02000012A (ru)
NO (1) NO20020087L (ru)
NZ (1) NZ516550A (ru)
PL (1) PL352685A1 (ru)
RU (1) RU2279883C2 (ru)
TR (1) TR200200766T2 (ru)
TW (1) TWI248364B (ru)
WO (1) WO2001003723A1 (ru)
YU (1) YU1402A (ru)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6818740B1 (en) 1997-04-17 2004-11-16 Whitehead Institute For Biomedical Research Inhibitors of HIV membrane fusion
US6150088A (en) 1997-04-17 2000-11-21 Whitehead Institute For Biomedical Research Core structure of gp41 from the HIV envelope glycoprotein
US6841657B2 (en) 1997-04-17 2005-01-11 Whitehead Institute For Biomedical Research Inhibitors of HIV membrane fusion
US7960504B2 (en) 1998-07-30 2011-06-14 Whitehead Institute For Biomedical Research Inhibitors of HIV membrane fusion
US6747126B1 (en) 1998-07-30 2004-06-08 Whitehead Institute For Biomedical Research Peptide inhibitors of HIV entry
JP4925540B2 (ja) 1999-12-16 2012-04-25 ホワイトヘッド インスチチュート フォアー バイオメディカル リサーチ ５−ヘリックスタンパク質
ATE345353T1 (de) 2001-05-31 2006-12-15 Conjuchem Biotechnologies Inc Langwirkende fusionspeptidinhibitoren gegen hiv- infektion
JP4267444B2 (ja) 2001-06-15 2009-05-27 エフ．ホフマン−ラ ロシュ アーゲー Ｇｐ４１フラグメントのアセチル化
JP4284412B2 (ja) * 2002-03-01 2009-06-24 独立行政法人産業技術総合研究所 細胞およびリポソームの固定化体とその固定化方法
US8292884B2 (en) 2002-08-01 2012-10-23 Levine Robert A Cardiac devices and methods for minimally invasive repair of ischemic mitral regurgitation
US7575750B2 (en) 2002-09-24 2009-08-18 Frontiers Biotechnologies Col, Ltd. Human immunodeficiency virus (HIV) gp41 peptide derivatives with enhanced solubility and antiviral activity
US7556813B2 (en) * 2002-09-27 2009-07-07 Trimeris, Inc. Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides
CA2521393A1 (en) * 2003-04-04 2004-10-14 Universite De Lausanne Peptabody for cancer treatment
WO2004106364A1 (en) * 2003-08-05 2004-12-09 Cornell Research Foundation, Inc. Stabilizing peptides and their use in the preparation of stabilized hiv inhibitors
AU2004308952A1 (en) 2003-12-23 2005-07-14 Centocor, Inc. Anti-retroviral agents, compositions, methods and uses
JP2007517522A (ja) * 2004-01-07 2007-07-05 トリメリス，インコーポレーテッド ＨＩＶｇｐ４１ＨＲ２由来の合成ペプチド、およびヒト免疫不全ウイルスの伝播を阻止する治療におけるその使用
MXPA06010505A (es) * 2004-03-15 2006-12-19 Nektar Therapeutics Al Corp Composiciones y conjugados, basados en polimeros, de inhibidores de ingreso de vih.
US7811577B2 (en) * 2004-06-01 2010-10-12 Merck Sharp & Dohme Corp. Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity
GB0426146D0 (en) 2004-11-29 2004-12-29 Bioxell Spa Therapeutic peptides and method
WO2006105993A2 (en) * 2005-04-05 2006-10-12 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Method for shielding functional sites or epitopes on proteins
TW200722436A (en) * 2005-10-21 2007-06-16 Hoffmann La Roche A peptide-immunoglobulin-conjugate
CN101415723B (zh) * 2006-02-02 2014-06-25 特里梅里斯公司 具有改良生物学特性的hiv融合抑制肽
US7682619B2 (en) 2006-04-06 2010-03-23 Cornell Research Foundation, Inc. Canine influenza virus
CN101088557A (zh) 2006-06-12 2007-12-19 天津市扶素生物技术有限公司 用于预防或治疗hiv感染的药用组合物及其应用
TW200817438A (en) * 2006-08-17 2008-04-16 Hoffmann La Roche A conjugate of an antibody against CCR5 and an antifusogenic peptide
WO2008019817A1 (en) 2006-08-17 2008-02-21 F. Hoffmann-La Roche Ag A conjugate of an antibody against ccr5 and an antifusogenic peptide
JP2010521478A (ja) * 2007-03-12 2010-06-24 トーマス・ジェファーソン・ユニバーシティ Ｈｉｖ−１侵入に対する強固に結合したｃ−ペプチド阻害剤
TW200902544A (en) 2007-03-13 2009-01-16 Hoffmann La Roche Peptide-complement conjugates
US20090068243A1 (en) * 2007-04-03 2009-03-12 Brian Bray Novel formulations for delivery of antiviral peptide therapeutics
WO2008144590A2 (en) * 2007-05-16 2008-11-27 Conjuchem Biotechnologies Inc. Long lasting modified antifusogenic peptide for preventing hiv infection
RU2496489C2 (ru) * 2007-05-24 2013-10-27 Дзе Борд Оф Риджентс Оф Дзе Юниверсити Оф Техас Систем Способы и композиции для лечения фенилкетонурии
US20090022720A1 (en) 2007-07-20 2009-01-22 Stephan Fischer Conjugate of an antibody against CD4 and antifusogenic peptides
WO2009030872A1 (en) * 2007-09-07 2009-03-12 Mats Axel Atterdag Persson Materials and methods for the treatment of hepatitis c
KR20100080812A (ko) * 2007-09-25 2010-07-12 트라이머리스, 인코퍼레이티드 치료용 항-ｈｉｖ 펩티드의 합성 방법
DK2252627T3 (en) 2008-01-24 2017-08-14 Esperance Pharmaceuticals MERGER CONSTRUCTION WITH LYTIC DOMAIN AND METHOD FOR PRODUCING AND USING SAME.
RU2548753C2 (ru) 2009-11-16 2015-04-20 Ипсен Фарма С.А.С. Фармацевтические композиции лигандов рецепторов меланокортинов
US9782454B2 (en) 2010-04-22 2017-10-10 Longevity Biotech, Inc. Highly active polypeptides and methods of making and using the same
JP5757639B2 (ja) 2010-09-14 2015-07-29 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ セルピンフィンガー融合ポリペプチド
WO2013127288A1 (zh) * 2012-02-27 2013-09-06 中国人民解放军军事医学科学院毒物药物研究所 抗hiv-1多肽及其用途
CN104039815A (zh) * 2012-02-28 2014-09-10 中国人民解放军军事医学科学院毒物药物研究所 用于抑制hiv的多肽及其作用靶点
WO2014070957A1 (en) 2012-10-30 2014-05-08 Esperance Pharmaceuticals, Inc. Antibody/drug conjugates and methods of use
US9789164B2 (en) 2013-03-15 2017-10-17 Longevity Biotech, Inc. Peptides comprising non-natural amino acids and methods of making and using the same
US10919904B2 (en) 2016-08-17 2021-02-16 North Carolina State University Northern-southern route to synthesis of bacteriochlorins
WO2018081832A1 (en) * 2016-10-31 2018-05-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Peptide fragments from filoviruses and their uses
US10836774B2 (en) 2016-11-30 2020-11-17 North Carolina State University Methods for making bacteriochlorin macrocycles comprising an annulated isocyclic ring and related compounds
AU2018326439A1 (en) * 2017-08-29 2020-04-16 Pharis Biotec Gmbh Protransduzin-D - improved enhancer of gene transfer
CN116162136A (zh) * 2021-11-24 2023-05-26 成都奥达生物科技有限公司 一种抗合胞病毒膜融合抑制剂

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS63258575A (ja) 1986-12-15 1988-10-26 レプリゲン　コーポレーション 昆虫細胞中でつくられる組換えｈｉｖエンベロープタンパク
EP0306912A3 (en) 1987-09-08 1989-07-05 Albany Medical College Immunogenic composites capable of selectively inducing antibody production and pharmaceutical compositions employing the same.
US5763160A (en) 1988-02-12 1998-06-09 United Biomedical, Inc. Synthetic peptides and process of using same for the detection of antibodies to human immunodeficiency virus (HIV) gp120 envelope protein, diagnosis of AIDS and pre-AIDS conditions and as vaccines
CA1341285C (en) * 1988-02-12 2001-08-14 Chang Yi Wang Synthetic peptides for the detection of antibodies to hiv gp120 envelope protein for diagnosis of aids and pre-aids conditions and as vaccines
US5122614A (en) * 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
IE904083A1 (en) * 1989-11-13 1991-05-22 Cambridge Biotech Corp Diagnostic proteins to test for more than one antibody
US5723129A (en) 1991-10-16 1998-03-03 University Of Saskatchewan GnRH-leukotoxin chimeras
US5357041A (en) * 1991-12-06 1994-10-18 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Heparin- and sulfatide-binding peptides from the type I repeats of human thrombospondin
GB9200117D0 (en) 1992-01-06 1992-02-26 Connaught Lab Production of recombinant chimeric proteins for vaccine use
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
ZA934199B (en) 1992-06-18 1994-01-10 Akzo Nv Carrier system against gnrh
DE69326069T2 (de) 1992-07-20 2000-03-23 Univ Durham Zusammensetzungen die die hiv replikation inhibieren
EP0673387B1 (en) 1992-12-11 1999-09-22 University Of Florida Materials and methods for control of pests
US5646167A (en) * 1993-01-06 1997-07-08 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamix acids
US5464933A (en) 1993-06-07 1995-11-07 Duke University Synthetic peptide inhibitors of HIV transmission
US6479055B1 (en) 1993-06-07 2002-11-12 Trimeris, Inc. Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
US5932462A (en) * 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
ES2093593T1 (es) 1995-05-05 1997-01-01 Hoffmann La Roche Proteinas obesas (ob) recombinantes.
US6019980A (en) 1995-06-07 2000-02-01 Connaught Laboratories Limited Nucleic acid respiratory syncytial virus vaccines
FR2739621B1 (fr) 1995-10-05 1997-12-05 Centre Nat Rech Scient Peptides utilisables comme vecteurs pour l'adressage intracellulaire de molecules actives
US6258782B1 (en) * 1998-05-20 2001-07-10 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
US6469136B1 (en) * 1999-07-07 2002-10-22 Trimeris, Inc. Methods and composition for peptide synthesis

Also Published As

Publication number Publication date
US7297784B2 (en) 2007-11-20
NO20020087D0 (no) 2002-01-08
BR0012287A (pt) 2002-04-02
US6656906B1 (en) 2003-12-02
CA2377677A1 (en) 2001-01-18
TWI248364B (en) 2006-02-01
YU1402A (sh) 2004-11-25
EP1206272A1 (en) 2002-05-22
CZ200288A3 (cs) 2002-06-12
RU2279883C2 (ru) 2006-07-20
HK1045259A1 (zh) 2002-11-22
TR200200766T2 (tr) 2002-10-21
PL352685A1 (en) 2003-09-08
KR100755418B1 (ko) 2007-09-05
IL147331A0 (en) 2002-08-14
CN1254271C (zh) 2006-05-03
KR20020029667A (ko) 2002-04-19
EP1206272A4 (en) 2003-01-02
AU6082200A (en) 2001-01-30
WO2001003723A1 (en) 2001-01-18
JP2003504344A (ja) 2003-02-04
MXPA02000012A (es) 2003-07-21
NZ516550A (en) 2004-05-28
HRP20020022A2 (en) 2004-02-29
CN1373669A (zh) 2002-10-09
WO2001003723A9 (en) 2002-07-25
US20030186874A1 (en) 2003-10-02
AR024699A1 (es) 2002-10-23

Similar Documents

Publication Publication Date Title
NO20020087L (no) Hybride polypeptider med forbedrede farmakokinetiske egenskaper
NO20005836L (no) Hybride polypeptider med forsterkede farmakokinetiske egenskaper
CY2013019I1 (el) Tροποποιημενα χιμαιρικα πολυπεπτιδια με βελτιωμενες φαρμακοκινητικες ιδιοτητες
DE60025345D1 (de) Spritzanordnung
ATE353329T1 (de) Heteroalkylamino-substituierte bicyclische stickstoffheterocyclen
DE60039612D1 (de) Verbundener konstruktionskörper
DE60032747D1 (de) Annäherungssensor
DE50014884D1 (de) Horizontalspritzgiessmaschine
PT1163264E (pt) Novos antagonistas de lhrh com propriedades de solubilidade melhoradas
DE60024807D1 (de) Pymetrozine solvate
DE29900980U1 (de) Formteil
FR2801425B1 (fr) Capacite integree a dielectrique hybride
ID26377A (id) Lampu fluoresens berbentuk lampu pijar
DE50003528D1 (de) Formkörper
DE59908327D1 (de) Verformungskörper
DE50012335D1 (de) Brennofen
DE29907215U1 (de) Kipptränke
ITMI990624A0 (it) Polipeptidi citotossici
ATA69399A (de) Verbundkörper
DE50005179D1 (de) Gesinterter keramischer Verbundkörper
DE10080648D2 (de) Manifold
ITMO990224A0 (it) Attacco conometrico perfezionato
FIU990391U0 (fi) Taskutuhkakuppi
NO993283D0 (no) Meiselverkt°y
NO992594D0 (no) Meiselverkt°y

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application